|
Synonyms: PF-05082566
Compound class:
Antibody
Comment: Utomilumab is a fully human IgG2 monoclonal antibody with agonist activity at the tumour necrosis factor (TNF) receptor, 4-1BB (TNFRSF9), being investigated for potential clinical anti-tumour activity [1].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| Utomilumab (PF-05082566) is in early stage clinical trials in patients with various solid and liquid tumour types. Click here to link to the PF-05082566 trials registered with ClinicalTrials.gov. Preliminary (and as yet unpublished) results from NCT02179918 (PF-05082566 in combination with the PD-1 checkpoint inhibitor pembrolizumab) indicate positive responses in 6 out of 23 patients with advanced cancers. |
| Mechanism Of Action and Pharmacodynamic Effects |
| Utomilumab acts as a ligand, activating 4-1BB and leading to enhanced T cell activity and cytokine production, which elicits improved destruction of cancer cells. It is hypothesised that combining this immune system activation with checkpoint inhibition (e.g. with anti-PD-1, or anti CTLA-4 antibodies) will offer more effective therapy against many types of cancer. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02179918 | A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036) | Phase 1 Interventional | Pfizer | ||
